Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1997 Dec;35(12):3112–3115. doi: 10.1128/jcm.35.12.3112-3115.1997

Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group.

M Wilson 1, J S Remington 1, C Clavet 1, G Varney 1, C Press 1, D Ware 1
PMCID: PMC230132  PMID: 9399504

Abstract

As a result of reports received by the Food and Drug Administration (FDA) of false-positive results obtained with FDA-cleared in vitro diagnostic kits for the detection of Toxoplasma-specific human immunoglobulin M (IgM) antibodies, an FDA-sponsored evaluation of six kits was performed. A battery of 258 serum specimens, including 30 specimens drawn 1 to 5 months after initial Toxoplasma infection and 228 specimens from Toxoplasma IgG-positive individuals, Toxoplasma IgG-negative individuals, rheumatoid factor-positive persons, and persons determined to be Toxoplasma IgM positive by commercially available assays, was assembled, randomly assorted, and coded. The battery was tested at the FDA with six commercially available kits, at the Palo Alto Medical Foundation (PAMF) by the PAMF double-sandwich IgM enzyme-linked immunosorbent assay (PAMF IgM ELISA), and at the Centers for Disease Control and Prevention (CDC) by the CDC EIA IgM. The results of the PAMF IgM ELISA that were obtained with the battery were considered to be the "gold standard" for this study; specificity rates were computed by considering the PAMF results to be 100% specific. Sensitivity and specificity rates were found to be as follows: CDC EIA IgM, 100 and 99.1%, respectively; Abbott IMx Toxo IgM, version 1, 100 and 77.5%, respectively; Abbott IMx Toxo IgM, version 2, 93.3 and 97.3%, respectively; Abbott Toxo-M EIA, 100 and 84.2%, respectively; BioMérieux Vitek VIDAS Toxo IgM, 100 and 98.6%, respectively; BioWhittaker Toxocap-M, 100 and 95.9%, respectively; Gull Toxo IgM, 97 and 85.6%, respectively; and Sanofi Diagnostics Pasteur Platelia Toxo IgM, 100 and 96.8%, respectively. Although the extent of false-positive reactions with these kits cannot be calculated because the study was retrospective and sample choices were biased, the results may be useful as an indicator of the relative specificities of these kits.

Full Text

The Full Text of this article is available as a PDF (123.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Decoster A., Lecolier B. Bicentric evaluation of Access Toxo immunoglobulin M (IgM) and IgG assays and IMx toxo IgM and IgG assays and comparison with Platelia Toxo IgM and IgG assays. J Clin Microbiol. 1996 Jul;34(7):1606–1609. doi: 10.1128/jcm.34.7.1606-1609.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Franco E. L., Walls K. W., Sulzer A. J. Reverse enzyme immunoassay for detection of specific anti-Toxoplasma immunoglobulin M antibodies. J Clin Microbiol. 1981 May;13(5):859–864. doi: 10.1128/jcm.13.5.859-864.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Liesenfeld O., Press C., Flanders R., Ramirez R., Remington J. S. Study of Abbott Toxo IMx system for detection of immunoglobulin G and immunoglobulin M toxoplasma antibodies: value of confirmatory testing for diagnosis of acute toxoplasmosis. J Clin Microbiol. 1996 Oct;34(10):2526–2530. doi: 10.1128/jcm.34.10.2526-2530.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Liesenfeld O., Press C., Montoya J. G., Gill R., Isaac-Renton J. L., Hedman K., Remington J. S. False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. J Clin Microbiol. 1997 Jan;35(1):174–178. doi: 10.1128/jcm.35.1.174-178.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Luyasu V., Robert A. R., Schaefer L., Macioszek J. Multicenter evaluation of a new commercial assay for detection of immunoglobulin M antibodies to Toxoplasma gondii. Multicenter Study Group. Eur J Clin Microbiol Infect Dis. 1995 Sep;14(9):787–793. doi: 10.1007/BF01690994. [DOI] [PubMed] [Google Scholar]
  6. Naot Y., Remington J. S. An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis. J Infect Dis. 1980 Nov;142(5):757–766. doi: 10.1093/infdis/142.5.757. [DOI] [PubMed] [Google Scholar]
  7. Sabin A. B., Feldman H. A. Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon Parasite (Toxoplasma). Science. 1948 Dec 10;108(2815):660–663. doi: 10.1126/science.108.2815.660. [DOI] [PubMed] [Google Scholar]
  8. Siegel J. P., Remington J. S. Comparison of methods for quantitating antigen-specific immunoglobulin M antibody with a reverse enzyme-linked immunosorbent assay. J Clin Microbiol. 1983 Jul;18(1):63–70. doi: 10.1128/jcm.18.1.63-70.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Teutsch S. M., Juranek D. D., Sulzer A., Dubey J. P., Sikes R. K. Epidemic toxoplasmosis associated with infected cats. N Engl J Med. 1979 Mar 29;300(13):695–699. doi: 10.1056/NEJM197903293001302. [DOI] [PubMed] [Google Scholar]
  10. Wilson M., Ware D. A., Walls K. W. Evaluation of commercial serodiagnostic kits for toxoplasmosis. J Clin Microbiol. 1987 Dec;25(12):2262–2265. doi: 10.1128/jcm.25.12.2262-2265.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES